2023-08-17 17:06:53 ET
More on BeiGene
- Sales Success Comes With Side Effects For Drug Maker BeiGene
- Heated Market For Dueling Blood Cancer Drugs Lands BeiGene In Court
- BeiGene Faces Patent Battle: Confronting Uncertainty In The Oncology Market
- BeiGene beats top and bottom line Q2 estimates
- BeiGene drug gets positive EMA panel opinion for esophageal cancer
- BeiGene wins FDA review to expand Brukinsa label for lymphoma
- Novartis ends licensing deal with BeiGene
- Seeking Alpha’s Quant Rating on BeiGene
- Earnings data for BeiGene
For further details see:
Jefferies starts BeiGene at buy, cites deep pipeline, Novartis partnership